Regulatory aspects of oncolytic virus products

Current Cancer Drug Targets

Volumn 7, Issue 2, 2007, Pages 203-208

  Yamaguchi, Teruhide ^a   Uchida, Eriko ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Cancer therapy; Gene therapy; Replicating virus

Indexed keywords

ONCOLYTIC VIRUS;

CANCER THERAPY; DNA REPLICATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STERILITY; DRUG SYNTHESIS; GENETIC ENGINEERING; GENETIC STABILITY; HUMAN; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VIRAL CONTAMINATION; VIRUS ATTENUATION; VIRUS SHEDDING;

ANIMALS; BIOTECHNOLOGY; CLINICAL TRIALS; CONSUMER PRODUCT SAFETY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; QUALITY CONTROL; RESEARCH DESIGN; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33847347612     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780058790     Document Type: Review

References (49)

1. Southam, C. M.; Moore, A. E. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 1952, 5, 1025-1034.
2. Huebner, R. J.; Rowe, W. P.; Schatten, W. E.; Smith, R. R.; Thomas, L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9, 1211-1218.
3. Russell, S. J. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur. J. Cancer 1994, 30A, 1165-1171.
4. Yamanishi, K.; Takahashi, M.; Kurimura, T.; Ueda, S.; Minekawa, Y. Studies on live mumps virus vaccine. 3. Evaluation of newly developed live mumps virus vaccine. Biken J. 1970, 13, 157-161.
5. Csatary, L. K.; Eckhardt, S.; Bukosza, I.; Czegledi, F.; Fenyvesi, C.; Gergely, P.; Bodey, B.; Csatary, C. M. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev. 1993, 17, 619-627.
6. Shimizu, Y.; Hasumi, K.; Okudaira, Y.; Yamanishi, K.; Takahashi, M. Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect. Prev. 1988, 12, 487-495.
7. Okuno, Y.; Asada, T.; Yamanishi, K.; Otsuka, T.; Takahashi, M.; Tanioka, T.; Aoyama, H.; Fukui, O.; Matsumoto, K.; Uemura, F.; Wada, A. Studies on the use of mumps virus for treatment of human cancer. Biken J. 1978, 21, 37-49.
8. Heicappell, R.; Schirrmacher, V.; von Hoegen, P.; Ahlert, T.; Appelhans, B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int. J. Cancer 1986, 37, 569-577.
9. European Medicines Agency (EMEA). Report from the CPMP Gene Therapy Expert Group Meeting 26th-27th February 2004. EMEA/CPMP/1879/ 04/Final, 2004.
10. Ries, S. J.; Brandts, C. H. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov. Today 2004, 9, 759-768.
11. Lin, E.; Nemunaitis, J. Oncolytic viral therapies. Cancer Gene Ther. 2004, 11, 643-664.
12. Russell, S. J. RNA viruses as virotherapy agents. Cancer Gene Ther. 2002, 9, 961-966.
13. Kinoh, H.; Inoue, M.; Washizawa, K.; Yamamoto, T.; Fujikawa, S.; Tokusumi, Y.; Iida, A.; Nagai, Y.; Hasegawa, M. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther. 2004, 11, 1137-1145.
14. Aghi, M.; Martuza, R. L. Oncolytic viral therapies - the clinical experience. Oncogene 2005, 24, 7802-7816.
15. Barber, G. N. VSV-tumor selective replication and protein translation. Oncogene 2005, 24, 7710-7719.
16. Stojdl, D. F.; Lichty, B. D.; tenOever, B. R.; Paterson, J. M.; Power, A. T.; Knowles, S.; Marius, R.; Reynard, J.; Poliquin, L.; Atkins, H.; Brown, E. G.; Durbin, R. K.; Durbin, J. E.; Hiscott, J.; Bell, J. C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4, 263-275.
17. Norman, K. L.; Lee, P. W. Reovirus as a novel oncolytic agent. J. Clin. Invest. 2000, 105, 1035-1038.
18. Stoeckel, J.; Hay, J. G. Drug evaluation: Reolysin - wild-type reovirus as a cancer therapeutic. Curr. Opin Mol. Ther. 2006, 8, 249-260.
19. Shmulevitz, M.; Marcato, P.; Lee, P. W. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005, 24, 7720-7728.
20. Kimata, H.; Takakuwa, H.; Goshima, F.; Teshigahara, O.; Nakao, A.; Kurata, T.; Sata, T.; Nishiyama, Y. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 2003, 50, 961-966.
21. Takakuwa, H.; Goshima, F.; Nozawa, N.; Yoshikawa, T.; Kimata, H.; Nakao, A.; Nawa, A.; Kurata, T.; Sata, T.; Nishiyama, Y. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol. 2003, 148, 813-825.
22. Teshigahara, O.; Goshima, F.; Takao, K.; Kohno, S.; Kimata, H.; Nakao, A.; Nishiyama, Y. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J. Surg. Oncol. 2004, 85, 42-47.
23. Mathis, J. M.; Stoff-Khalili, M. A.; Curiel, D. T. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 2005, 24, 7775-7791.
24. Post, D. E.; Khuri, F. R.; Simons, J. W.; Van Meir, E. G. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum. Gene Ther. 2003, 14, 933-946.
25. Bischoff, J. R.; Kirn, D. H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey, A.; McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274, 373-376.
26. Ries, S.; Korn, W. M. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 2002, 86, 5-11.
27. Nakamura, T.; Peng, K. W.; Harvey, M.; Greiner, S.; Lorimer, I. A.; James, C. D.; Russell, S. J. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 2005, 23, 209-214.
28. Hermiston, T. W.; Kuhn, I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. 2002, 9, 1022-1035.
29. Freytag, S. O.; Khil, M.; Stricker, H.; Peabody, J.; Menon, M.; DePeralta-Venturina, M.; Nafziger, D.; Pegg, J.; Paielli, D.; Brown, S.; Barton, K.; Lu, M.; Aguilar-Cordova, E.; Kim, J. H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62, 4968-4976.
30. US Food and Drug Administration (FDA). Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. 1998.
31. US Food and Drug Administration (FDA). Guidance for FDA Review Staff and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). DRAFT GUIDANCE. 2004.
32. European Medicines Agency (EMEA). Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. CPMP/BWP/3088/99. 2001.
33. Ministry of Health, Labour and Welfare (MHLW). Notification of Pharmaceutical Affairs Bureau, Yaku-hatsu No.1062: Guidance for Assuring the Quality and Safety of the Gene Therapy Products. (in Japanese) 1995.
34. ICH Harmonized Tripartite Guideline. ICH-Q5D: Derivation and Characterization of Cell Substrates Used for Production of BioTechnological/ Biological Products. 1997.
35. Working, P. K.; Lin, A.; Borellini, F. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 2005, 24, 7792-7801.
36. Bernt, K.; Liang, M.; Ye, X.; Ni, S.; Li, Z. Y.; Ye, S. L.; Hu, F.; Lieber, A. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J. Virol. 2002, 76, 10994-11002.
37. Graham, F. L.; Smiley, J.; Russell, W. C.; Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36, 59-74.
38. Fallaux, F. J.; Bout, A.; van der Velde, I.; van den Wollenberg, D. J.; Hehir, K. M.; Keegan, J.; Auger, C.; Cramer, S. J.; van Ormondt, H.; van der Eb, A. J.; Valerio, D.; Hoeben, R. C. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 1998, 9, 1909-1917.
39. Lusky, M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum. Gene Ther. 2005, 16, 281-291.
40. Farson, D.; Tao, L.; Ko, D.; Li, Q.; Brignetti, D.; Segawa, K.; Mittelstaedt, D.; Harding, T.; Yu, D. C.; Li, Y. Development of Novel E1-Complementary Cells for Adenoviral Production Free of Replication-Competent Adenovirus. Mol. Ther. 2006, 14, 305-311.
41. ICH Harmonised Tripartite Guideline. ICH-Q5A: Viral Safety Evaluation of Biotechnology Products derived from Cell Lines of Human or Animal Origin. 1997.
42. Hutchins, B.; Sajjadi, N.; Seaver, S.; Shepherd, A.; Bauer, S. R.; Simek, S.; Carson, K.; Aguilar-Cordova, E. Working toward an adenoviral vector testing standard. Mol. Ther. 2000, 2, 532-534.
43. Alemany, R.; Balague, C.; Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 2000, 18, 723-727.
44. Raper, S. E.; Chirmule, N.; Lee, F. S.; Wivel, N. A.; Bagg, A.; Gao, G. P.; Wilson, J. M.; Batshaw, M. L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80, 148-158.
45. Lichtenstein, D. L.; Wold, W. S. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 2004, 11, 819-829.
46. Makower, D.; Rozenblit, A.; Kaufman, H.; Edelman, M.; Lane, M. E.; Zwiebel, J.; Haynes, H.; Wadler, S. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 2003, 9, 693-702.
47. Small, E. J.; Carducci, M. A.; Burke, J. M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D. C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Onco-lytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. Mol. Ther. 2006, 14, 107-117.
48. DeWeese, T. L.; van der Poel, H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; DeJong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; DeMarzo, A. M.; Piantadosi, S.; Yu, D. C.; Chen, Y.; Henderson, D. R.; Carducci, M. A.; Nelson, W. G.; Simons, J. W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001, 61, 7464-7472.
49. Todo, T.; Feigenbaum, F.; Rabkin, S. D.; Lakeman, F.; Newsome, J. T.; Johnson, P. A.; Mitchell, E.; Belliveau, D.; Ostrove, J. M.; Martuza, R. L. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol. Ther. 2000, 2, 588-595.